Vir Biotechnology insider plans sale of 1,530 shares

Vir Biotechnology received a notice of proposed stock sales under Rule 144.

Rhea-AI Filing Summary

Vir Biotechnology received a notice of proposed stock sales under Rule 144. The filing covers planned sales of 1,530 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of 11,918.09 and listing on NASDAQ.

The shares were acquired on 02/13/2026 through restricted stock vesting from the issuer as compensation, with payment also dated 02/13/2026. The notice states that the person for whose account the securities are to be sold does not know of any undisclosed material adverse information about Vir’s operations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Vir Biotechnology (VIR) Form 144 disclose in this filing?

The filing discloses a planned sale of 1,530 Vir Biotechnology common shares under Rule 144. The shares are to be sold through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of 11,918.09 based on the information provided.

How many Vir Biotechnology (VIR) shares are planned for sale under Rule 144?

The notice covers a proposed sale of 1,530 common shares of Vir Biotechnology. These shares were acquired as restricted stock vesting and are to be sold through Fidelity Brokerage Services LLC on NASDAQ, reflecting an aggregate market value of 11,918.09 in the filing.

How were the Vir Biotechnology (VIR) shares in this Form 144 acquired?

The 1,530 Vir Biotechnology common shares were acquired on 02/13/2026 via restricted stock vesting from the issuer as compensation. The date of payment is also listed as 02/13/2026, indicating the shares arose from a compensation-related equity grant.

What market details are given for the Vir Biotechnology (VIR) Form 144 sale?

The proposed sale involves 1,530 common shares with an aggregate market value of 11,918.09. The filing lists NASDAQ as the securities exchange and names Fidelity Brokerage Services LLC as the broker handling the transaction for the planned Rule 144 sale.

How many Vir Biotechnology (VIR) shares are outstanding in this Form 144?

The filing states that 139,125,032 common shares of Vir Biotechnology are outstanding. This figure provides context for the planned Rule 144 sale of 1,530 shares, showing the proposed transaction is small relative to the total shares outstanding.

What representation does the selling person make in the Vir Biotechnology (VIR) Form 144?

The person for whose account the shares are to be sold represents that they do not know any material adverse information about Vir Biotechnology’s current or prospective operations that has not been publicly disclosed, as required in the Rule 144 notice language.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 03:46 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002037272
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Vir Biotechnology, Inc.
SEC File Number	001-39083
Address of Issuer	1800 OWENS STREET SUITE 900 SAN FRANCISCO CALIFORNIA 94158
Phone	415-906-4324
Name of Person for Whose Account the Securities are To Be Sold	Sabatini Brent
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	1530	11918.09	139125032	02/13/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/13/2026	Restricted Stock Vesting	Issuer			1530	02/13/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	02/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jessica Spraker, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Brent Sabatini.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)